Last reviewed · How we verify

Joint injection with triamcinolone hexacetonide

Federal University of São Paulo · FDA-approved active Small molecule

Triamcinolone hexacetonide is a long-acting corticosteroid that suppresses local inflammation and immune responses when injected directly into a joint.

Triamcinolone hexacetonide is a long-acting corticosteroid that suppresses local inflammation and immune responses when injected directly into a joint. Used for Intra-articular inflammation in rheumatoid arthritis, Osteoarthritis joint pain and inflammation, Other inflammatory joint conditions.

At a glance

Generic nameJoint injection with triamcinolone hexacetonide
SponsorFederal University of São Paulo
Drug classCorticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRheumatology/Orthopedics
PhaseFDA-approved

Mechanism of action

Triamcinolone hexacetonide binds to glucocorticoid receptors in synovial tissue, reducing the production of pro-inflammatory cytokines and inhibiting immune cell infiltration. The hexacetonide ester formulation provides sustained local release, allowing for prolonged anti-inflammatory effects with minimal systemic absorption when administered as an intra-articular injection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: